Using oncolytic viruses to improve glioma treatment
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
This study is looking at a new way to treat glioblastoma, a tough type of brain cancer, by using a special virus that helps destroy tumor cells and boost the immune system, with the hope of improving outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11018506 on NIH RePORTER |
What this research studies
This research investigates the use of oncolytic adenoviruses, specifically Delta-24-RGDOX, to treat glioblastoma, a type of brain cancer with a very low survival rate. The approach combines direct tumor cell destruction with the activation of the immune system to enhance anti-tumor responses. By administering immune agonists alongside the adenovirus, the goal is to overcome the immunosuppressive environment of gliomas and improve treatment outcomes for patients. The research builds on previous findings that showed some patients had durable responses to similar treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent glioblastoma who have limited treatment options.
Not a fit: Patients with non-glioma brain tumors or those who are not eligible for experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients with glioblastoma.
How similar studies have performed: Previous clinical trials with oncolytic adenoviruses have shown promising results, indicating that this approach has potential based on earlier successes.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Fueyo, Juan — University of Tx Md Anderson Can Ctr
- Study coordinator: Fueyo, Juan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.